Chronic subdural hematoma （CSDH） is one of the most common diseases requiring neurosurgical treatment， and conventional treatment methods， including surgery， tend to have an uncertain therapeutic effect. According to the expert consensus on pharmacotherapy for CSDH， the postoperative recurrence rate of CSDH can reach 33%， and some patients have to undergo multiple surgeries due to such recurrence. With the rise of endovascular treatment， middle meningeal artery embolization has provided a new treatment strategy for CSDH， and whether used alone or in combination with surgical operation， it can effectively reduce the recurrence rate of CSDH and the incidence rate of related complications. ［Journal of International Neurology and Neurosurgery, 2023, 50(6): 92-95］